Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)

BACKGROUND: The hepatic artery infusion (HAI) of irinotecan, oxaliplatin and 5-fluorouracil with intravenous cetuximab achieved outstanding efficacy in previously treated patients with initially unresectable liver metastases from colorectal cancer. This planned study aimed at the identification of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lévi, Francis, Karaboué, Abdoulaye, Saffroy, Raphaël, Desterke, Christophe, Boige, Valerie, Smith, Denis, Hebbar, Mohamed, Innominato, Pasquale, Taieb, Julien, Carvalho, Carlos, Guimbaud, Rosine, Focan, Christian, Bouchahda, Mohamed, Adam, René, Ducreux, Michel, Milano, Gérard, Lemoine, Antoinette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625679/
https://www.ncbi.nlm.nih.gov/pubmed/28817838
http://dx.doi.org/10.1038/bjc.2017.278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625679/
https://www.ncbi.nlm.nih.gov/pubmed/28817838
http://dx.doi.org/10.1038/bjc.2017.278

Ejemplares similares